Dr. Eran R. Andrechek

Department of Physiology
Michigan State University, USA



2003 Ph.D., McMaster University, Biology

1997 B.Sc., McMaster University, Molecular Biology and Biotechnology

Publications (Selected)

  1. T58A Myc induced tumors have reduced dependency upon Kras mutations and initiate tumors with similarities to human-claudin low breast cancer. Hollern, D., Yuwanita, I. and E.R. Andrechek.
  2. Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc Induced TumorsKenichiro Fujiwara, Inez Yuwanita, Daniel Hollern and Eran R. Andrechek Cancer Research, e-pub January 18, 2011 DOI: 10.1158/0008-5472. CAN-10-2386
  3. Mouse Models of Cancers: Opportunities to Address Heterogeneity of Human Cancer and Evaluate Therapeutic Strategies. E.R. Andrechek and J.R. Nevins, Journal of Molecular Medicine, e-pub 24 June 2010 DOI: 10.1007/s00109-010-0644-z
  4. Heterogeneity in MYC-Induced Mammary Tumors Determines Outcomes Following Loss of Myc Activity J.Y. Leung, E.R. Andrechek, R. D.Cardiff, and J.R. Nevins Under Review at Oncogene, 8/30/2011
  5. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. E. R. Andrechek, R.D. Cardiff, J.T. Chang, M.L. Gatza, A. Potti, and J. R. NevinsPNAS 2009 106:16387-16392; published online before print September 4, 2009
  6. A Role for E2F Activities in Determining the Fate of Myc-Induced Lymphomagenesis
  7. R.E. Rempel, S. Mori, M. Gasparetto, M.A. Glozak, E.R. Andrechek, S.B. Adler, N. Laakso, A.S. Lagoo, R. Storms, C. Smith and J.R. Nevins PLOS GENETICS, 2009 Sep;5(9):e1000640. Epub 2009 Sep 11.
  8. Utilization of genomic signatures to identify phenotype-specific drugs.S. Mori, J.T. Chang, E. R. Andrechek, A. Potti and J.R. Nevins. PLoS One. 2009 Aug 28; 4(8):e6772.
  9. Anchorage-independent cell growth signature identifies tumors with metastatic potential.S. Mori, J.T. Chang, E.R. Andrechek, N. Matsumura, T. Baba, G. Yao, J.W. Kim, M.L. Gatza, S.Murphy and J.R. Nevins. Oncogene, Advance online publication, 1 June 2009; doi:10.1038/onc.2009.139.
  10. Patterns of Cell Signaling Pathway Activation That Characterize Mammary Development E.R. Andrechek, S. Mori, J.T. Chang, R.E. Rempel and J.R. Nevins. Development, 2008 135(14):2403-2413.
  11. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. P.H. Giangrande, J. Zhang, A. Tanner, A.D. Eckhart, R.E. Rempel, E.R. Andrechek, J.M. Layzer, J.R. Keys, P.O. Hagen, J.R. Nevins, W.J. Koch and B.A. Sullenger. PNAS, 2007 104(32):12988-93.
  12. Cell-type specific delivery of siRNAs with aptamer-siRNA chimeras. J.O. McNamara II*, E.R. Andrechek*, R.E. Rempel, E. Gilboa, B.A. Sullenger, P.H. Giangrande Nature Biotechnology, 2006 24(8):1005-15.* - authors contributed equally to this work.
  13. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. E.R. Andrechek, D. White and W.J. Muller Oncogene 2005 24(5):932-7.
  14. Expression, Location and Interactions of ErbB2 and its Intramembrane Ligand Muc4 (Sialomucin Complex) in Rat Mammary Gland During Pregnancy S. A. Price, E.R. Andrechek, N. Idris, P. Li, M. Rong, J. Zhang, C.A.C. Carraway, W.J. Muller and K.L. Carraway Journal of Cellular Physiology 2005 203(1):44-53.
  15. Germline expression of an oncogenic erbB2 allele confers resistance to erbB2 induced mammary tumorigenesis. E.R. Andrechek, W.R. Hardy, M.A. Laing and W.J. Muller PNAS, 2004 101(14):4984-9.
  16. Gene expression profiling of Neu induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2 expressing human breast cancers.E.R. Andrechek, M.A. Laing, A.A. Girgis-Gabardo, P.M. Siegel and W.J. Muller Cancer Research, 2003 63(16):4920-6.
  17. ErbB2 is Required for Muscle Spindle and Myoblast Cell Survival. E.R. Andrechek, W.R. Hardy, A. Girgis-Gabadro, R. Perry, R. Butler, F.L. Graham, R.C. Kahn, M.A. Rudnicki and W.J. Muller.Mol. Cell Biol. 2002 22(13):4714-22.
  18. Mol. Cell Biol. Cover Illustration- 2003, 23(3)
  19. Mol. Cell Biol. Cover Illustration- 2002, 22(14)
  20. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neudefine mouse mammary gland adenocarcinomas induced by mutant HER2/neu. C. Montagana, E.R. Andrechek, H. Padilla-Nash, W.J. Muller and T. Ried Oncogene 2002 21(6):890-8.
  21. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. E.R. Andrechek, W.R. Hardy, P.M. Siegel, M.A. Rudnicki, R.D. Cardiff and W.J. Muller. PNAS, 2000 97(7):3444-9.
  22. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. M.J. Rauh, V. Blackmore, E.R. Andrechek, C.G. Tortorice, R. Daly, V.K. Lai, T. Pawson, R.D. Cardiff, P.M. Siegel and W.J. Muller. Mol. Cell Biol.1999 19(12):8169-79
  23. Developmental Timing of Activated erbB2 Expression Plays a Critical Role in the Induction of Mammary Tumors. (Invited Review). E.R Andrechek and W.J. Muller  Cell Cycle 2004 Sep1;3(9).
  24. Tyrosine kinase signaling in breast cancer: Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. (Invited Review). E.R. Andrechek and W.J. Muller Breast Cancer Res.2000 2:211-216